Diabetes represents a major threat to the health of the working population, and constitutes an immense social and economic burden. Rodent models of streptozotocin (STZ)-induced or genetic diabetes are commonly used in diabetes research. Diabetic animals have a high mortality rate and require intensive care and characterization. Diabetic complications tend to occur only long after the onset of diabetes, and long-term maintenance and monitoring of diabetic animals are labor-intensive and associated with high costs. The objective of this Core is to centralize the induction, breeding, monitoring, maintenance, and use of diabetic animal models, and to coordinate the sharing of diabetic animal tissues among the investigators. In the past nine years of this COBRE, the Diabetic Animal Core has provided service, diabetic animals, and animal tissues to 35 investigators, including the COBRE Promising Junior Investigators (PJIs), members of the Harold Hamm Diabetes Center (HHDC), and other diabetes researchers. This Core has provided support to 208 publications and 29 funded NIH grants on campus. The Core has greatly increased the efficiency of diabetes research using diabetic animal models and has reduced costs for PJIs and other diabetes researchers at the HHDC. The Core has become an essential and unique facility for diabetes research in Oklahoma. Considering the excellent service of this Core and rapid growth in diabetes research on our campus, the HHDC started to provide funds to subsidize this Core in Phase II of our COBRE. The HHDC is also committed to supporting the transition of this Core to an independent research core facility supported by the HHDC after the completion of the COBRE Phase III. In Phase III, we will further improve the Core services and start the transition of this Core to a HHDC-supported facility. In Phase III, we will induce diabetes by STZ injection in rats and mice, and breed genetic diabetic animals as requested by investigators. We will also monitor diabetes and collect ?clinical data? on diabetic animals. We will coordinate sharing diabetic animal tissues by different users and expand the diabetic animal tissue bank. Further, this Core will provide training or technical assistance for specialized assays of diabetic complications. Through these efforts, this Core will provide support for the Pilot Projects funded by the COBRE, greatly enhance diabetes research in Oklahoma and contribute to further growth of the HHDC. It will also attract more local basic scientists into diabetes research and facilitate recruitment of new diabetes researchers into Oklahoma. This Core will contribute to the development of new treatments for diabetes and its complications.

Public Health Relevance

Diabetic animal models are important for diabetic research and for the development of new drugs to treat diabetes and diabetic complications. This Core will provide centralized service to maintain, care and use diabetic models These efforts will contribute to the development of new treatments for diabetes..

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM122744-02
Application #
9520206
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Wang, Bing; Li, Pui-Kai; Ma, Jian-Xing et al. (2018) Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci 59:3630-3642
Shin, Younghwa; Moiseyev, Gennadiy; Petrukhin, Konstantin et al. (2018) A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis 1864:2420-2429
Chen, Jianglei; Fan, Jun; Wang, Shirley et al. (2018) Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1. Hypertension 71:877-885
Chen, Qian; Qiu, Fangfang; Zhou, Kelu et al. (2017) Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPAR?. Diabetes 66:1671-1682
Vanlandingham, Phillip A; Nuno, Didier J; Quiambao, Alexander B et al. (2017) Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:2095-2105
Malechka, Volha V; Moiseyev, Gennadiy; Takahashi, Yusuke et al. (2017) Impaired Rhodopsin Generation in the Rat Model of Diabetic Retinopathy. Am J Pathol 187:2222-2231
Qiu, Fangfang; Liu, Zhen; Zhou, Yueping et al. (2017) Decreased Circulating Levels of Dickkopf-1 in Patients with Exudative Age-related Macular Degeneration. Sci Rep 7:1263
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Qiu, Fangfang; Matlock, Greg; Chen, Qian et al. (2017) Therapeutic Effects of PPAR? Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 58:5065-5075
Deng, Guotao; Moran, Elizabeth P; Cheng, Rui et al. (2017) Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy. Invest Ophthalmol Vis Sci 58:5030-5042

Showing the most recent 10 out of 12 publications